Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 23, 2017. The document serves as a report of a foreign issuer pursuant to Rule 13a-16 of the Securities Exchange Act of 1934. The primary content is an announcement of positive clinical trial results for the respiratory franchise, specifically regarding the drug Relvar Ellipta (fluticasone furoate/vilanterol).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory announcement regarding clinical study outcomes rather than a financial earnings report.
Material Changes and Clinical Results
The filing details the results of a non-inferiority lung function study comparing once-daily Relvar Ellipta (FF/VI) 100/25 against twice-daily Seretide Accuhaler (FP/SAL) 250/50 in patients with well-controlled asthma.
- Primary Endpoint: The study met its primary endpoint. Patients switching to once-daily Relvar Ellipta maintained lung function comparable to those on twice-daily Seretide.
- Statistical Data: The difference in lung function was +19mL (95% CI: -11mL, +49mL). The lower bound of the 95% confidence interval (-11mL) fell above the non-inferiority margin of -100mL.
- Comparative Efficacy: Both ICS/LABA combinations demonstrated statistically significant differences in favor of the combination therapy compared to fluticasone propionate (FP) monotherapy (p<0.001).
- Safety Profile: Incidences of serious adverse events (SAEs) and adverse events of special interest were consistent with the known safety profile of FF/VI.
Outlook, Management Commentary, and Risks
Management Commentary: Eric Dube, SVP and Global Head of Respiratory Franchise at GSK, stated that the results provide confidence that a once-daily treatment option is available for patients who struggle with twice-daily regimens, offering greater physician choice. Mike Aguiar, CEO of Innoviva, Inc., noted the results provide additional evidence for patients currently on twice-daily ICS/LABA to experience similar benefits with a once-daily regimen.
Regulatory Outlook: The study design was agreed upon with European regulatory authorities. GSK intends to submit this data to the European Medicines Agency (EMA). Results will be shared in future publications and presentations.
Risks and Contingencies:
- Forward-Looking Statements: Both GSK and Innoviva include standard cautionary statements that actual results may differ materially from projections due to risks and uncertainties.
- Safety Warnings: The filing reiterates known risks for Relvar Ellipta (Breo Ellipta in the US) and Seretide Accuhaler (Advair Diskus in the US), including increased risk of asthma-related death with LABA use, pneumonia (particularly in COPD patients), cardiovascular effects, and systemic corticosteroid effects.
- Contraindications: Both drugs are contraindicated for the relief of acute bronchospasm and in patients with hypersensitivity to active ingredients.
Investor Verification Checklist
- Verify the submission timeline and acceptance of the new data by the European Medicines Agency (EMA).
- Monitor future publications and presentations for detailed safety data and subgroup analyses.
- Review the impact of these results on the commercial strategy for Relvar Ellipta versus Seretide Accuhaler in the European market.
- Check for any updates on the partnership agreement between GSK and Innoviva regarding royalty revenues for respiratory assets.
- Confirm that no new safety signals emerged during the 24-week treatment period that were not previously known.